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The interaction of a large number of extracellular proteinswith heparan sulfate
(HS) regulates their transport and effector functions, but the degree of molecu-
lar specificity underlying protein–polysaccharide binding is still debated.
The 15 paracrine fibroblast growth factors (FGFs) are one of the paradigms
for this interaction. Here, we measure the binding preferences of six FGFs
(FGF3, FGF4, FGF6, FGF10, FGF17, FGF20) for a library of modified heparins,
representing structures in HS, andmodel glycosaminoglycans, using differen-
tial scanning fluorimetry. This is complemented by the identification of the
lysine residues in the primary and secondary binding sites of the FGFs by a
selective labelling approach. Pooling these data with previous sets provides
good coverage of the FGF phylogenetic tree, deduced from amino acid
sequence alignment. This demonstrates that the selectivity of the FGFs for
binding structures in sulfated polysaccharides and the pattern of secondary
binding sites on the surface of FGFs follow the phylogenetic relationship of
the FGFs, and so are likely to be the result of the natural selection pressures
that led to the expansion of the FGF family in the course of the evolution of
more complex animal body plans.1. Introduction
The glycosaminoglycan heparan sulfate (HS) regulates many aspects of cell
communication by means of binding to over 435 extracellular proteins and
thereby controlling their activities [1] (reviewed in [2–4]). Two classic examples
are the activation of antithrombin III by the polysaccharide, which contributes
to the regulation of coagulation [5], and the control of the transport and effector
functions of the paracrine fibroblast growth factors (FGFs) by their binding to
HS [6–10]. A major challenge is to understand the structural basis of the inter-
actions of proteins with HS and to what extent any molecular specificity and
selectivity of these interactions is of functional significance.
HS consists of repeating disaccharide units joined by 1–4 linkages. The HS
chains are always synthesized attached to a core protein to formHSproteoglycans.
It is the core protein that directs the HS chains to their functional location, which
can be the cell surface or the extracellular matrix. Heparin, often used as an exper-
imental proxy for HS on account of its underlying structural similarity, is
nevertheless a more sulfated structure. The repeating units of HS consist of a glu-
curonic acid (GlcA) or its C5 epimer iduronic acid (IdoA) and D-glucosamine
(GlcN). The glucosamine may be N-acetylated (GlcNAc), N-sulfated (GlcNS) or
unsubstituted (GlcN). The biosynthetic pathway has been proposed to have
two branches [11]: the major branch is the chain modified by the N-deacetylase/
Table 1. Nomenclature and structures of chemically modiﬁed heparin structures. I stands for iduronate, and A stands for the amino sugar glucosamine.
aNumbers refer to the ring position of carbon atoms. The average number of sulfate groups per disaccharide is also indicated.
analogue
predominant
repeat IdoUA-2 GlcN-6 GlcN-2 IdoUA-3 GlcN-3a
sulfate groups
per disaccharide
D1 (heparin) I2SA
6SNs SO3
2 SO3
2 SO3
2 OH OH 2.4
D2 I2SA
6SNAc SO3
2 SO3
2 COCH3 OH OH 1.8
D3 I2OHA
6SNs OH SO3
2 SO3
2 OH OH 1.9
D4 I2SA
6SNs SO3
2 OH SO3
2 OH OH 1.8
D5 I2OHA
6SNAc OH SO3
2 COCH3 OH OH 1.2
D6 I2SA
6OHNAc SO3
2 OH COCH3 OH OH 0.8
D7 I2OHA
6OHNs OH OH SO3
2 OH OH 0.8
D8 I2OHA
6OHNAc OH OH COCH3 OH OH 0
D9 I2S,3SA
6S
3SNs SO3
2 SO3
2 SO3
2 SO3
2 SO3
2 4.4
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mine with an N-sulfate group [12,13] and may be followed by
C5 epimerization with C5 epimerase [14] and O-sulfation with
2-O, 6-O and 3-O sulfotransferases [15,16]; the minor branch
arises from the position in the scheme at which that the HS epi-
merase applies on the chain at an early point,which converts the
GlcA–GlcNAc to IdoA–GlcNAc. Because almost all the other
modifications depend on the presence of N-sulfated glucosa-
mine, the result is that HS chains have a domain structure:
NA domains with no sulfation structure, NS domains of
highly sulfated structures and NA/NS domains comprising
mixed disaccharides of GlcNAc and GlcNS [17] (reviewed in
[12,18]). The sulfated structures are considered to be of
functional significance, forming the protein binding domains [2].
The FGF family of 22 proteins has been divided into seven
subfamilies by phylogenetic analysis [19]. Based on theirmech-
anisms of action, FGFs can be classified into three types:
intracrine, paracrine and endocrine. Only the paracrine FGFs
bind to HS. Evidence for control by HS of FGF transport
comes from a variety of experimental systems. For example,
mutations in the gene encoding sugarless (sgl) and sulfateless
(sfl), which are part of the Drosophila HS chain biosynthetic
machinery, were identified as producing similar phenotypes
to Wingless (Wg) or Hedgehog (Hh) signalling mutants [13].
Interactions with HS occurring in the extracellular matrix
have been shown directly to regulate the diffusion of FGFs
[8,20] and so can determine the shape of FGF concentration
gradients in development [21,22], as well as the storage and
release of FGFs in tissue homeostasis [9,10]. The growth
factor/morphogen-type signals generated by FGFs require
the assembly of the ternary complex of FGF ligand, FGF recep-
tor (FGFR) and HS, which engages both the ligand and
receptor [6,7]. Thus, in this respect, HS acts as a co-receptor.
In terms of the specificity of interactions of proteins with
HS, there are different paradigms and views. One paradigm
is the activation of antithrombin III by its binding to a specific
pentasaccharide sequence in heparin [23], which has been suc-
cessfully transformed into a synthetic anticoagulant, Arixtra
[24,25]. It was the higher affinity saccharide unit salt-eluted
from an antithrombin III affinity column that was originally
identified, but it was not the only sequence that bound anti-
thrombin III and was able to activate it. More recent findings
are that activity relates to thermal stabilization of antithrombin
III [26], and many oligosaccharide structures have now beenshown both to possess a high affinity for antithrombin III
and to exert strong anticoagulant activity [27,28]. With other
proteins, there is even less consensus. Thus, with FGFs,
highly specific binding structures in heparin and in HS have
been sought [29]. In other experiments, however, the con-
clusion was that the charge density of the polysaccharide was
themajor determinant of binding selectivity (reviewed in [30]).
In a recent attempt to understand the extent, if any, of selec-
tivity of FGFs for binding to HS, the molecular basis of the
interactions between six FGFs from five subfamilies and HS
was characterized in depth. The results suggested that there is a
degreeof selectivity inFGF–heparin interactions, and this reflects
the evolution of the FGF familymembers [31],whichparallels the
specificity of FGF ligands for FGFRs [32]. However, this work is
limited in its coverage: two FGFs from one subfamily and one
from each of four other subfamilies. Therefore, alternative expla-
nations are quite possible.Consequently, herewe characterize the
interactionswithHS of a further six FGFs from two perspectives.
The preference of FGFs for a particular sugar structure has been
determined using differential scanning fluorimetry (DSF) and a
library of chemically modified heparins, heparin-derived oligo-
saccharides and model glycosaminoglycan. A protect and label
approach is then used to identify lysine side chains involved in
heparinbindingandsomap theprimaryandsecondaryHSbind-
ing sites in the FGFs. Pooling thepresent datawith those acquired
previously [31,33,34] demonstrates that the FGFs show clear
selectivity for binding structures and that this, alongwith thepat-
ternof secondarybinding sites on the surface of theFGFs, follows
the phylogeny established by amino acid sequence alignment.
Thus, the molecular basis of the interactions of FGFs with HS
and their preference for particular isoforms of the FGFR have fol-
lowed the expansion and specialization of the FGF family that
occurred during the course of the evolution of themore complex
body plans of animals.2. Material and methods
2.1. Materials
Heparin (17 kDa average molecular mass, Celsus Lab,
Cincinnati, OH) was used in all assays, and as the starting
material for the production of modified derivatives and oligo-
saccharides. Different chemically modified heparin derivatives
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described [36], whereas oligosaccharides with degrees of
polymerization (dp) dp2–dp12 were obtained from Iduron
(Manchester, UK). Porcine mucosal HS, hyaluronic acid
(HA, not sulfated) and chondroitin sulfate C (CS-C, average sul-
fate per disaccharide unit, 1) were from Sigma (Gillingham,
Dorset, UK); Dermatan sulfate (DS, average sulfate per
disaccharide unit, 1) were from Iduron.
2.2. Recombinant human fibroblast growth factors
cDNA encoding Histag-FGF4 (UniProt accession number
P08620; residues 31–206) was transformed into C41 (DE3)
cells and expressed by inducing with 1 mM isopropyl 1-thio-
b-D-galactopyranoside at 378C for 3 h. After cell lysis by soni-
cation and clarification by centrifugation at 38 000g for 30 min,
the supernatant was loaded onto a 1 ml affinity HiTrap heparin
HP column (GE Healthcare, Amersham, Bucks, UK), washed
with buffer (50 mM Tris–Cl, 0.3M NaCl, pH 7.2, 30 ml) and
then elutedwith 1 MNaCl in 50 mMTris buffer. FGF4 required
further purification with a cation-exchange HiTrap 1 ml SP HP
column to remove the contaminants, asdescribedpreviously for
FGF2 [33]. HaloTag (HT)-FGF17 and HT-FGF6 were expressed
and purified as described [37]; the HT-FGF17 protein was
digested overnight by mixing with TEV protease at ratio 40 : 1.
The sample was then loaded on a HiTrap Q column. FGF17
eluted in the flow through fraction, because it did not bind to
this anion-exchange matrix, whereas the anionic HaloTag
protein bound to the column. The FGF17 was then further
purified by affinity chromatography on a 1 ml Hitrap heparin
column. Histag-FGF3, HT-FGF6, Histag-FGF10 and Histag-
FGF20 were expressed and purified, as described [37]. Because
proteins were produced in Escherichia coli, they will not
be glycosylated.
2.3. Size exclusion chromatography–multi-angle laser
light scattering
Analysis of the solutionmolecularmasswas performedby sep-
aration of proteins on 25 ml Superdex 200 HR10/300 columns
(GEHealthcare) connected in serieswith aWyatt Dawn8þ and
Wyatt Optilab T-rEX (Wyatt Technology, Haverhill, UK) at
228C. Samples (100 ml, 100 mg protein) were filtered and then
applied to the column, which was developed in 150 mM
NaCl buffered with either 50 mM HEPES or 50 mM Tris–Cl,
both pH 7.4 at a flow rate of 0.75 ml min21.
2.4. Differential scanning fluorimetry
DSF was performed with a 7500 fast real-time PCR (RT-PCR)
instruction (software version 1.4.0, Applied Biosystems,
Paisley, UK), as described [31,33]. The different sugars
(100 mM, 3.5 ml in HPLC grade water) and FGFs (50 mM,
3.5 ml) as 10-fold concentrated stock solutions, phosphate-
buffered saline (PBS: NaCl 137 mM, KCl 2.7 mM, Na2HPO4
10 mM, KH2PO4 1.8 mM; 24.5 ml), and freshly prepared
100-fold stock solution Sypro Orange dye (3.5 ml; Life Tech-
nologies, Paisley UK) were added to a Fast Optical 96 Well
Reaction plate (Life Technologies) kept on ice. After sealing
with Optical Adhesive Film (Life Technologies), the plate
was directly analysed in the RT-PCR instrument with a heat-
ing cycle covering a gradient between 32 and 818C in 99 stepsof 20 s. First derivatives of the melting curves were calculated
with ORIGIN 7 (OriginLab Corp., Northampton, UK). For
each sugar, at least two experiments each in triplicate was
performed and analysed. The mean melting temperature Tm
and the standard error (s.e.) were calculated based on the
six repeats. Data were normalized as: [Tm x2 Tm PBS]/[Tm
hep 2 Tm PBS], where Tm x is the Tm of protein in the pres-
ence of the heparin derivative; Tm PBS is the Tm of the
protein in PBS, and Tm hep is the Tm of the protein in the
presence of heparin. The relative stability of protein in PBS
buffer was set to 0, whereas the relative stability of the protein
in the presence of heparin was set to 1.
2.5. Protect and label identification of lysines involved
in heparin binding (structural proteomics)
2.5.1. Lysine protection
The identification of lysines in heparin binding sites (HBS)was
according toOri et al. [34] withminormodifications. A heparin
minicolumn was made by placing a plastic air filter at the end
of a small pipette tip into which 30 ml of AF-heparin beads
(Tosoh Biosciences, Stuttgart, Germany; binding capacity
4 mg antithrombin III ml21 resin) was packed. A 5 ml syringe
was used to pack the minicolumn and dispense buffer. The
heparin column was equilibrated four times with 50 ml of PB
150 buffer (17.9 mM Na2HPO4, 2.1 mM NaH2PO4, 150 mM
NaCl, pH 7.8). A minimum of 40 mg FGF protein was loaded
onto the heparin column, and the loading was repeated three
times with the same sample. After binding, the column was
washed with PB 150 buffer four times. To acetylate exposed
lysines, the minicolumn was then quickly rinsed with 20 ml
of PB 150 containing 50 mM sulfo-NHS–acetate (Life Technol-
ogies, Paisley, UK) and then incubated for 5 min with 20 ml of
fresh PB 150 containing 50 mM sulfo-NHS–acetate at room
temperature. After acetylation, the minicolumn was washed
with 50 ml of PB 150 buffer, and acetylated protein was
eluted from heparin with 2  20 ml elution buffer (45 mM
Na2HPO4, 5 mM NaH2PO4, 2 M NaCl, pH 7.8).
2.5.2. Heparin binding site lysine biotinylation
Acetylated protein was diluted with 200 ml of PB buffer and
concentrated with a 5 kDa MWCO centrifugal filter (Sartor-
ius, Epsom, UK) by centrifugation for 15 min at 11 200g.
The volume was adjusted to 37.2 ml with PB buffer, and
any remaining amino groups were biotinylated by the
addition of 2.8 ml 145 mM NHS–biotin (Life Technologies)
in dimethylsulfoxide and 30 min incubation at room temp-
erature. The biotinylation reaction was quenched with 4 ml
of 1 M Tris, pH 7.5. Then, the sample was transferred to a
desalting centrifugal column (7 kDa MWCO, Thermo Scienti-
fic, Rockford, UK), covered with 70 ml HPLC grade water and
centrifuged for 2 min. Samples were frozen at 2808C for
10 min and dried by centrifugal evaporation.
2.5.3. Protein digestion
Dried sample was dissolved with 25 ml 8 M urea, 400 mM
NH4HCO3, pH 7.8 and 2.5 ml 45 mM DTT and incubated for
15 min at 568C. Then, the samples were carbamidomethylated
with 2.5 ml of freshly made 0.1 M iodoacetamide for 15 min at
room temperature in the dark. Proteins were dilutedwith 70 ml
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Figure 1. Stabilization effect of heparin on FGF3. Differential scanning fluorimetry of 5mM FGF3 in the presence of varying concentrations of heparin. (a) Melting
curve profiles of FGF3 (5 mM) with a range of heparin concentrations (0–100 mM). (b) First derivative of the melting curves of FGF3 in (a). (c) Heparin-dependence
of the melting temperature (Tm) of FGF3, FGF10, FGF4, FGF17, FGF20 and HT-FGF6, Tm is the mean of triplicates+ s.e.
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protease (trypsin, chymotrypsin, thermolysin or Glu-C;
Promega, Southampton, UK).2.5.4. Identification of labelled peptides
Biotinylated/acetylated peptides were made up to 0.5% (w/v)
trifluoroacetic acid (TFA) and desalted using C18 Zip Tips
(Millipore). The latter were pre-wetted with 100% (v/v) aceto-
nitrile (ACN) and then pre-equilibrated with 0.1% (w/v) TFA
in water. The peptides were loaded on the Zip Tip and then
washed with 10 ml 0.1% (w/v) TFA. Finally, the peptides
were eluted with two aliquots of 4–6 ml 50% (v/v) ACN. The
samples were concentrated by rotary evaporation. Analyses
were performed on a MALDI-TOF mass spectrometer
(Waters, Manchester, UK). The MS spectra were produced by
MASSLYNX v.4.0 and then analysed with the MS-digest tool of
the PROTEIN PROSPECTOR package v. 5.12.4 with the following
parameters: consideredmodification, acetyl (K), biotin (K), car-
bamidomethyl (C), carboxymethyl (C); protease used, trypsin/
chymotrypsin, thermolysin or Glu-C; missed cleavages, 5;
minimum–maximum mass: 800–4000.3. Results
We have used two approaches and multiple representatives of
the different human heparin binding FGF subfamilies, FGF3
and 10 (FGF7 subfamily), FGF16 and 20 (FGF9 subfamily),FGF4 and 6 (FGF4 subfamily), and FGF8 and 17 (FGF8 sub-
family) to gain an insight into the selectivity and structural
basis of the interaction of FGFs with glycosaminoglycan. DSF
makes use of an environment sensitive dye (Sypro Orange),
which when bound to aromatic residues produces a high
fluorescence; these residues are exposed when proteins are
thermally denatured [33]. This allows measurement of the
extent of stabilization of the structure of FGFs that occurs
upon binding different glycosaminoglycan structures. The pro-
tect and label approach identifies lysine residues that are
engaged in direct interactions with heparin and so determines
the likely binding sites of the polysaccharide in the FGFs. It is
capable of identifying lysine residues in both the primary,
higher affinity canonical binding site, and in the much lower
affinity secondary binding sites [31,34].3.1. Thermal stabilization of fibroblast growth factors
by interaction with heparin
The change in fluorescence was measured as temperature was
increased with 5 mM of each FGF, and then the first derivative
was calculated to determine the melting temperature. Only
one melting curve and corresponding derivative per sample
is shown in the figures for clarity. Complete datasets are
shown in the electronic supplementary material. In the case
of FGF3, as the concentration of heparin increased, the melt-
ing curves were displaced to the right, indicating that the
FGF3 melting temperature increased (figure 1a). It should
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of the dye Sypro orange to exposed aromatic residues, which
causes an increase in fluorescence as the FGF3 unfolds, and
the aggregation of the unfolded FGF3, which will re-bury
these side chains and cause a decrease in fluorescence [33].
The amplitude of the change in fluorescence thus depends
on the total concentration of protein and its aggregation. It
is clear that in the presence of heparin the unfolded FGF3
aggregates less, because the amplitude of fluorescence is
higher (figure 1a). The first derivative of the melting curves
identifies the melting temperature (figure 1b), which can
then be plotted as a function of heparin concentration
(figure 1c). Collectively, these experiments show that heparin
has a concentration-dependent effect on the thermal stability
of all the FGFs tested, because their melting temperature pro-
gressively increased as the concentration of heparin increased
(figure 1c). The melting temperatures (Tm) of FGF3 and
FGF17 are 368C and 37.58C, respectively, whereas the Tm of
FGF4 (49.58C), FGF10 (41.68C) and FGF20 (52.28C) [38,39]
are considerably higher (figure 1c). In the case of FGF6, the
protein aggregates when the N-terminal HaloTag fusion
protein is removed [37], so the DSF assay was performed on
the fusion protein. Two distinct peaks are observed, one at
46.58C and the other at 58.58C (electronic supplementary
material, figure S3b,c). The lower melting temperature
(46.58C) is assigned to FGF6 for two reasons. First, the Tm of
purified HaloTag corresponds to the second peak (electronic
supplementary material, figure S3b), whereas the peak at
46.58C is shifted to higher temperature when the protein is
incubated with heparin (figure 1c) and only the FGF6 moiety
binds the polysaccharide [37]. Thus, not only are FGF4, FGF6,
FGF10 and FGF20 more stable than FGF3 and FGF17 in the
absence of heparin, but also, interestingly, human FGF3 and
FGF17 would under these conditions be unstable at normal
body temperature (figure 1c).
To determine the effects of binding heparin, a range of
heparin concentrations (0–100 mM) were tested against a
fixed concentration (5 mM) of FGFs, and the melting tempera-
ture was calculated at each concentration of polysaccharide.
The melting curves show that a stabilizing effect of heparin
on FGF3 and FGF10 is apparent from 0.5 (heparin–FGF
molar ratio, 1 : 10) to 2.5 mM heparin (heparin–FGF molar
ratio, 1 : 2) and is then unchanged at higher concentrations of
heparin (figure 1c and electronic supplementarymaterial, S1c).
The melting temperature of FGF6 was increased by heparin.
Although the signal from the more stable HaloTag overlapped
in part that from FGF6 when the latter was fully stabilized by
heparin, the point of inflection associated with the increase in
fluorescence arising from the unfolding of the FGF6 moiety
of the fusion protein remained distinct (electronic supplemen-
tary material, figure S3b). Therefore, this approach could
be used to measure the relative stabilizing effect of the inter-
action of FGF6 with glycosaminoglycans. The effect
of heparin on the melting temperature of FGF4, FGF6 and
FGF17 is similar, with stabilization becoming apparent at
0.5 mM heparin (heparin–FGF, 10 : 1) and reaching a maxi-
mum around 2.5 mM heparin (heparin–FGF, 1 : 2). However,
the stabilizing effect of heparin on FGF20, which is apparent
at 0.5 mM heparin, does not reach a maximum even with
100 mM heparin, and so is distinct from the other four FGFs.
The thermal stabilization of FGF20 by heparin was the lowest
at 108C, whereas for FGF4, FGF6, FGF10 and FGF17 it
ranged from 11 to 158C and was 178C for FGF3. Thus, inthe case of FGF3 and FGF17, binding to heparin raises their
melting temperature well above body temperature.3.2. Analysis of sugar binding selectivity by differential
scanning fluorimetry
The structures in the polysaccharide required for binding
these FGFs were then determined by measuring the stabiliz-
ation effect of a library of model glycosaminoglycans and
their derivatives. The molar ratio of FGF–polysaccharide
used in this experiment was approximately 1 : 2 (FGF,
5 mM; polysaccharide, 10 mM).
FGF3, a member of the FGF7 subfamily according to
amino acid sequence alignment, was similarly stabilized
by unmodified heparin and any of the singly desulfated
heparins (table 1, D2–D4; figure 2a). However, the doubly
desulfated heparins with just a 6-O-sulfate or N-sulfate
(table 1, D5 and D7) stabilized FGF3 to 40% and 25% of the
level observed with heparin, respectively, whereas heparin
with just 2-O-sulfate was without a detectable effect. Totally
desulfated heparin was also without effect. FGF3 was most
stabilized by persulfated heparin, whereas HS was as effec-
tive as the doubly desulfated N-sulfated or 6-O sulfated
heparins, D5 and D6. FGF3 did not have a detectable inter-
action with HA or CS-C, but DS clearly did bind, albeit not
as well as HS. A dp4 was the shortest oligosaccharide able
to stabilize FGF3 with a maximum effect at dp10, which
stabilized FGF3 to an extent similar to full-length heparin
(figure 2b). FGF3 did not discriminate between the different
cationic forms of heparin, because these all had the same sta-
bilizing effect (figure 2c). Thus, FGF3 has a clear preference
for a saccharide structure with any two of N-, 2-O and 6-O
sulfate and is able to bind structures with doubly desulfated
heparin containing just a 6-O-sulfate or an N-sulfate, whereas
a dp10 is likely to represent the full-length binding structure
in the polysaccharide.
In the case of FGF10, another member of the FGF7 subfam-
ily, there was no discernible difference in the stabilizing effect
of heparin and the singly desulfated heparins (table 1, D2–
D4; figure 3a). However, all three doubly desulfated heparins
(D5–D7) had a similar stabilizing effect, which was approxi-
mately 50–70% of that seen with heparin. Totally desulfated
heparin and HA failed to bind FGF10, whereas FGF10 bound
persulfated heparin more effectively than heparin and HS
only slightly more weakly. FGF10 also bound both CS-C and
DS, though the former more weakly. A heparin-derived dp4
oligosaccharide provided substantial binding and maximum
binding was seen with a dp8, indicating that this is the likely
minimum-sized fragment of the polysaccharide required for
interaction. FGF10 may also have a slight preference for the
Ca2þ, Zn2þ and Cu2þ cation forms of heparin. Thus, the bind-
ing preferences of FGF10 are similar but not identical to those
of FGF3. Compared with FGF3, FGF10 has a less marked pre-
ference for singly over doubly desulfated heparins, it does not
appreciably distinguish between any of the three doubly desul-
fated heparins, and has a wider range of glycosaminoglycan
species (CS-C as well as DS) with which it can interact
(figures 1b,c and 2b,c).
For FGF4, there was a greater thermal stabilization by
heparin than by any of the singly desulfated heparins
(figure 4a). Moreover, among the singly desulfated heparins,
FGF4 had a preference for polysaccharides with both 2-O
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(see ‘Differential scanning fluorimetry’). Thermal stabilization effect of (a) chemically modified heparins (table 1, D2–D9), and other glycosaminoglycan (HS, HA, CS
and DS), (b) heparin-derived oligosaccharides, ranging from dp2 to dp12 and (c) cation-modified heparin forms. Results are the mean of triplicates after
normalization+ s.e.
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O sulfate (D3), or 2-O and 6-O sulfate (D2). There was no
appreciable effect of the doubly desulfated heparins on thethermal stability of FGF4. These data suggest that the core rec-
ognition structure of FGF4 in the polysaccharide involves a 2-O
and N-sulfated structure. The lower stabilization observed
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Figure 4. Differential scanning fluorimetry (DSF) analysis of binding of glycosaminoglycan derivatives to FGF4. DSF of 5 mM FGF4 was performed in the presence of
a range of heparin-based poly- and oligosaccharides (all 10 mM) and the thermal stabilization relative to the PBS control (¼0) and heparin (¼1) was calculated
(see ‘Differential scanning fluorimetry’). Thermal stabilization effect of (a) chemically modified heparins (table 1, D2–D9), and other glycosaminoglycan (HS, HA, CS,
and DS), (b) heparin-derived oligosaccharides, ranging from dp2 to dp12 and (c) cation-modified heparin forms. Results are the mean of triplicates after
normalization+ s.e.
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Figure 5. Differential scanning fluorimetry (DSF) analysis of binding of glycosaminoglycan derivatives to HT-FGF6. DSF of 5 mM HT-FGF6 was performed in the
presence of a range of heparin-based poly- and oligosaccharides (all 10 mM) and the thermal stabilization relative to the PBS control (¼0) and heparin (¼1) was
calculated (see ‘Differential scanning fluorimetry’). Thermal stabilization effect of (a) chemically modified heparins (table 1, D2–D9), and other glycosaminoglycan
(HS, HA, CS, and DS) and (b) heparin-derived oligosaccharides, ranging from dp2 to dp12. Results are the mean of triplicates after normalization+ s.e., and an
apparent absence of error bar is due to a small s.e.
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containing this motif are relatively rare in this material. FGF4
also bound DS, though weakly, but did not bind to HA or
CS-C (figure 4a). FGF4 did not interact detectably with a dp4,
and a dp6 was the minimal fragment required for binding.
Maximal binding, equivalent to that observed with heparin,
was achievedwith a dp12 (figure 4b). Little effect was observed
for the different cation coordinated forms of heparin, indicating
that this parameter, which changes the conformation of the
polysaccharide chain [40], does not, at least in the case of the
heparin polysaccharide, influence the binding of FGF4
(figure 4c).
FGF6 is another member of the FGF4 subfamily, and
HT-FGF6 was more effectively stabilized by heparin than the
singly desulfated heparins (figure 5a). Of the latter, heparinswith a 2-O-sulfated iduronate bound better than D3, which
lacks this sulfate group, and there was a slight preference
for D2 (GlcNAc, 6S, IdoA 2S) over D4 (GlcNS, IdoA 2S;
figure 5a). With the exception of 2-O-sulfated heparin, the
doubly desulfated heparins did not have a measureable stabil-
ization effect on HT-FGF6, which highlights the preference of
FGF6 for a structure containing 2-O-sulfate (figure 5a). HT-
FGF6 bound persulfated heparin as effectively as native
heparin, but its interaction with HS was similar to that with
the singly desulfated heparin lacking Ido2S. No binding to
HA, CS-C or DS was detected (figure 5a). The minimum size
and maximum size of oligosaccharide required for binding to
FGF6 was dp6 and dp12, respectively (figure 5b).
FGF17 bound the three singly desulfated heparins similarly
to heparin and the doubly desulfated heparins more weakly
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Figure 6. Differential scanning fluorimetry (DSF) analysis of binding of glycosaminoglycan derivatives to FGF17. DSF of 5 mM FGF17 was performed in the presence
of a range of heparin-based poly- and oligosaccharides (all 10 mM) and the thermal stabilization relative to the PBS control (¼0) and heparin (¼1) was calculated
(see ‘Differential scanning fluorimetry’). Thermal stabilization effect of (a) chemically modified heparins (table 1, D2–D9), and other glycosaminoglycan (HS, HA, CS,
and DS), (b) heparin-derived oligosaccharides, ranging from dp2 to dp12 and (c) cation-modified heparin forms. Results are the mean of triplicates after
normalization+ s.e.
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with either a 2-O or a 6-O sulfate, compared with heparin with
just an N-sulfate (figure 6a). FGF17 did not bind desulfated
heparin or HA, but bound persulfated heparin and HS simi-
larly to heparin. It also interacted with DS to a similar extent
as the singly desulfated heparins and more weakly with
CS-C. FGF17 required at least a dp4 oligosaccharide for bind-
ing and maximal binding was observed with a dp8. It might
have a slight preference for Zn2þ coordinated heparin over
other cationic forms of the polysaccharides (figure 6b,c).
Heparin was more effective at stabilizing FGF20 than any
of the singly desulfated heparins (figure 7a). FGF20 had a
weak interaction with the doubly desulfated heparin posses-
sing just 6-O-sulfate or 2-O-sulfate, whereas there was no
detectable interaction with heparin possessing just an N-
sulfate, which suggests a preference for the former two
sulfation positions. The stabilizing effects of CS-C and DS on
FGF20 were similar to that seen with HS. The minimum size
of oligosaccharide required for binding to FGF20 was dp10,
whereas the maximum size of oligosaccharide used in this
assay, dp12, only stabilized the protein to around 40% of the
extent observed with heparin (figure 7b). The binding of
FGF20 to the polysaccharide was markedly affected by the
coordinating cations: the divalent cation (Ca2þ, Zn2þ or
Cu2þ) coordinated heparins were twice as effective in stabiliz-
ing FGF20 as heparins coordinated to a monovalent cation
(Na1þ and K1þ; figure 7c).3.3. Identification of lysines involved in heparin binding
by protect and label
The lysine residues involved in binding heparin in the FGFs
were determined by the ‘protect and label’ approach, wherelysines in binding sites are protected with acetyl groups,
when the FGFs are bound to heparin [34]. Following release
of the FGF from heparin, the newly exposed lysines that
had been involved in binding were labelled with biotin and
identified by mass spectrometry. The nomenclature of the
HBSs is that used previously [31,34], where the canonical
heparin binding site is HBS1, and the secondary sites
are HBS2–4.
3.4. FGF7 subfamily (FGF3/FGF10)
Initial experiments with FGF3 and FGF10 identified just one
peptide with biotinylated lysines, Lys-47 in FGF3 and Lys-81
in FGF10 both in strand b1 (table 2). This was considered
to be due to the use of chymotrypsin to cleave the protein,
which may produce peptides from these FGFs that are
either too long or too short for detection with MALDI-MS.
To identify further peptides, FGF3 and FGF10 were digested
with trypsin (cleaves at Arg residues only, owing to the pro-
tect and label procedure) and thermolysin (cleaves at Pro,
His, Asp, Glu residues), as modifications of the published
method [34]. By changing the protease used to cleave the
lysine-modified protein, a substantial number of biotinylated
lysine residues were identified in FGF3. Lys-160, Lys-168,
Lys-174, Lys-204 and Lys-214 were found to be biotinylated.
These residues are located in the loops between strands b10
and b11 and between strands b11 and b12 and C-terminal
to strand b12. They correspond to the HBS1 of FGF3, pre-
dicted by sequence alignment (figure 8) [31]. In addition,
two other lysine residues, which are close to the above resi-
dues of the canonical HBS1, were biotin-labelled: Lys-53,
which lies between strands b1 and b2, and Lys-101, which
is between strands b6 and b7. Thus, these two residues are
likely to be part of the canonical binding site, which,
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Figure 7. Differential scanning fluorimetry (DSF) analysis of binding of glycosaminoglycan derivatives to FGF20. DSF of 5 mM FGF20 was performed in the presence
of a range of heparin-based poly- and oligosaccharides (all 10 mM) and the thermal stabilization relative to the PBS control (¼0) and heparin (¼1) was calculated
(see ‘Differential scanning fluorimetry’). Thermal stabilization effect of (a) chemically modified heparins (table 1, D2–D9), and other glycosaminoglycan (HS, HA, CS
and DS), (b) heparin-derived oligosaccharides, ranging from dp2 to dp12 and (c) cation-modified heparin forms. Results are the mean of triplicates after
normalization+ s.e.
Table 2. Summary of peptides of FGF3 and of FGF10 identiﬁed by lysine-targeted protect and label. Labelled peptides were identiﬁed by MALDI-Q-TOF and
analysed by MS-digest from the package PROTEINPROSPECTOR v. 5.12.3. A full list of identiﬁed peptides is provided in the electronic supplementary material, table
S1. The three proteases used for protein digestion were trypsin (TRY), thermolysin (THE) and chymotrypsin (CHY). The spectrums were shown in the electronic
supplementary material, ﬁgure S7–S11.
peptide sequence protease residue HBS spectrum
FGF3 1 ATK(biotin)YHLQ (THE) 51–57 1 S8
2 AMNK(biotin)RGR (THE) 98–104 1 S8
3 LWYVSVNGK(biotin)GRPR (TRY) 152–164 1 S7
4 RGFK(biotin)TR (TRY) 165–170 1 S7
5 TQK(biotin)SSLFLPR (TRY) 172–181 1 S7
6 QLQSGLPRPPGK(biotin)GVQPR (TRY) 193–209 1 S7
7 QK(biotin)QSPDNLEPSHVQASR (TRY) 213–229 1 S7
8 EHLGGAPRRRK(biotin)L (CHY) 37–48 4 S9
FGF10 1 QMYVALNGK(biotin)GAPR (TRY) 175–187 1 S10
2 RGQK(biotin)TR (TRY) 188–193 1 S10
3 K(biotin)NTSAHFLPMVVHS (TRY) 195–208 1 S10
4 RK(biotin)LFSFTK(biotin)Y (CHY) 80–88 1/3 S11
5 IEKNGKVSGTK (2xbiotin) (TRY) 92–102 4 S10
6 YLAMNK(biotin/acetyl)K(biotin/acetyl)GK(biotin/acetyl)LY (CHY) 131–141 4 S11
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the primary sequence, but neighbouring in the folded
protein. However, biotinylated Lys-47 on strand b1 is distant
from the canonical binding site. Along with the neighbouring
arginine (Arg-44–46), this would be part of the secondary
binding site termed HBS3 in FGF2 [34]. The amino acids in
FGF3 corresponding to HBS4 identified in FGF7 are arginineand asparagine (figure 8; [31]), which would not be detected
by the lysine-targeted protect and label used here. Thus,
FGF3 may also possess an HBS4, but this remains to be
established.
Lys-87, Lys-184, Lys-191 and Lys-195 were all labelled in
FGF10 (table 2). These lysine residues are in the canonical
HBS1 of FGF10, as predicted by sequence alignment
(a)
(b)
(c)
(d )
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HBS-4
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b1
b1
b6
b12
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Figure 8. Sequence alignment of human FGF subfamilies. The sequences were aligned with CLUSTALX and Dendroscope [41,42].
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(Lys-125, Lys-126 and Lys-128) of FGF10 were found to be both
acetylated and biotinylated (figure 9). This has been observed
previously in other proteins [34,44], and is considered to be
due to the local dissociation of a lysine side chain from its inter-
action with the polysaccharide. In the presence of the NHS–
acetate used in the protection step, the transiently dissociated
lysine side chain becomes acetylated, and this would likelypreclude its re-binding to the polysaccharide. Because the
protein remains bound, these lysines must form part of the
binding site that is relatively dynamic over the timescale of
the protection step, but the remainder of the binding site
is not dynamic, such that the FGF10 remains bound to the
heparin column. Two biotinylated lysines were also identified
in peptide ‘IEKNGKVSGTK’ (residues 92–102). Owing to the
position of these residues on the surface of FGF10, they are
K70
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K86
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K160 K168
K174
labelled lysines
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other residues
180° 180° 
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Figure 9. Position of biotinylated lysines in FGF3 (residues 56–202) and in FGF10 (69–207) identified by structural proteomics mapped onto their predicted three-
dimensional structures. The published structure of FGF10 (69–207; PDB 1NUN) [43] was used to generate a model of the structure of FGF3. Labelled lysines are
coloured in blue and literature annotated and/or predicted lysines in HBS1 are coloured in yellow. The lysines overlapping with the literature annotated and pre-
dicted aligned canonical HBS1 lysines are coloured in green. (a,b,e,f ) Ribbon diagram; (c,d,g,h) corresponding molecular surface. (b,d ) 1808 back view of (a,c); ( f,h),
1808 back view of (e,g).
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viously and inferred in FGF3 [31] (figure 9). HBS4 lies
orthogonal to HBS1 in all three proteins, thus the binding of
the polysaccharide to these two sites is likely to be mutually
exclusive. Similar to FGF3, the biotinylated Lys-81 located in
strand b1 of FGF10 has also been identified to be part of
HBS3. Because the alignedHBS3 on FGF7 has arginine residues
rather than lysines, it was not detected [31]. However, the
identification of HBS3 in FGF3 and FGF10 strongly suggests
that the corresponding sequence in FGF7 has the same function.3.5. FGF4 subfamily (FGF4/FGF6)
For FGF4, Lys-183, Lys-186, Lys-188 and Lys-189 in the area
between the b10 strand and b12 strand were found to be bio-
tinylated (table 3). These lysine residues correspond to the
HBS1 of FGF4 predicted by sequence alignment (figure 10).
The mutation to alanine of Lys-183 and Lys-188 in FGF4 had
previously identified these residues as being part of the cano-
nical HBS1 [45]. Moreover, another three labelled lysine
residues are physically adjacent: Lys-142 is in the loop between
the b6 strand and b7 strand; Lys-144 is on the b7 strand; Lys-
147 is in the loop between the b9 strand and b10 strand. These
six residues can be considered to delineate the canonical HBS1
of FGF4 (figure 10). Further biotinylated lysines (Lys-65, Lys-
81 and Lys-158) were identified. They are aligned with a sec-
ondary HBS, HBS3, in other FGFs (figure 8) [31,34]. Similar
to FGF4, FGF6 has two HBSs: HBS1, which is identified by bio-
tinylated Lys-144, Lys-185 and Lys-194 (separately, loopbetween b6 strand and b7 strand, area between b10 strand
and b12 strand); and HBS3, which includes Lys-83 towards
the N-terminal of strand b1 and Lys-158 on the b8 strand
(figure 10; tables 4 and 5).3.6. FGF8 subfamily (FGF17)
In the case of FGF17, the predicted canonical HBS1 contains
arginine but no lysine residues and, therefore, no peptides
were identified between strands b10 and b12. However,
Lys-82 and Lys-85, located in the loop between strands b3
and b4, Lys-100 on strand b5, Lys-106 on strand b6 and
Lys-119, Lys-123 and Lys-125 on strand b7 and the loop
between strands b7 and b8 were all found to be biotinylated.
These residues are physically adjacent to the region between
strand b10 and b12, where the core of the HBS1 of FGFs is
predicted to be located. In addition, FGF17 has an HBS2,
which includes Lys-176, Lys-191 and Lys-193 at the C-
terminus. The aspartic acid (Asp-121) of FGF18 enlarges the
negative border formed by two glutamic acid residues
(Glu-103 and Glu-105), the result of which is that Lys-82
and Lys-100 are part of the extended HBS2. In contrast,
Asp-121 of FGF18 is Ser-121 in FGF17, which consequently
has a smaller negatively charged border along its HBS1 and
Lys-82 and Lys-100 are now likely to be part of an extended
HBS1. These data demonstrate how changes in the residues
surrounding HBS1 (in this instance Asp to Ser) can alter the
structure of an HBS and provide subtle difference between
members of the same subfamily (figure 11).
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Figure 10. Position of biotinylated lysines in FGF4 (residues 79–206) and in FGF6 (residues 47–174) identified by structural proteomics mapped onto their pre-
dicted three-dimensional structures. The published structure of FGF4 (79–206; PDB 1IJT) [45] was used to generate a structure of FGF6. Labelled lysines are coloured
in blue and literature annotated and/or predicted lysines in HBS1 are coloured in yellow. The lysines overlapping with the literature annotated and predicted aligned
canonical HBS1 lysines are coloured in green. (a,b,e,f ) Ribbon diagram; (c,d,g,h) corresponding molecular surface. (b,d) 1808 back view of (a,c); ( f,h), 1808 back view
of (e,g).
Table 3. Summary of peptides of FGF4 and of FGF6 identiﬁed by lysine-targeted protect and label. Labelled peptides were identiﬁed by MALDI-Q-TOF and
analysed by MS-digest from the package PROTEINPROSPECTOR v/ 5.12.3. A full list of identiﬁed peptides is provided in the electronic supplementary material, table
S1. The three proteases used for protein digestion were trypsin (TRY), thermolysin (THE) and chymotrypsin (CHY). The spectrums were shown in the electronic
supplementary material, ﬁgure S12–S16.
peptide sequence protease residue HBS spectrum
FGF4 1 VAMSSK(biotin)GK(biotin)LY (CHY) 137–146 1 S12
2 LPNNYNAYESYK(biotin)YPGMF (CHY) 162–178 1 S12
3 LSK(biotin)NGK(biotin)TK(biotin)K(biotin)GNRVSPT (THE) 181–196 1 S13
4 AQPK(biotin)EAAVQSGAGDY (THE) 62–76 3 S14
5 LLGIK(biotin)RL (CHY) 77–83 3 S12
6 FK(biotin)EILLPNNYN (THE) 157–167 3 S14
FGF6 1 SALFVAMNSK(biotin)GR (TRY) 135–146 1 S15
2 IALSK(biotin)Y (CHY) 181–186 1 S16
3 GSK(biotin)VSPIMTVTHFLPR (TRY) 192–207 1 S15
4 SRAGLAGEIAGVNWESGYLVGIK(biotin)RQRR (TRY) 61–87 3 S15
5 LYATPSFQEEC(carbamidomethyl)K(biotin)FR (TRY) 147–160 3 S15
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For FGF20, Lys-183, Lys-197, Lys-208 and Lys-212 located in
strand b9, the loop between strand b10 and strand b11, and
the loop between strand b11 and strand b12 were biotinylated
and these correspond to the predictedHBS1 by sequence align-
ment [31]. Two further lysine residues (Lys-148 and Lys-183)
that are located in the area between strand b6 and strand b7
were also identified to be biotinylated. Because these two
lysines are physically adjacent to the canonical binding site,they were considered to be an extension of the HBS1. The bio-
tinylated Lys-231 located in the C-terminus is quite close to
Arg-90, Arg-91 and Arg-92, which may form the HBS3
(figure 12), although, arginine residues cannot be identified
by the NHS chemistry used here. In any event, FGF20 pos-
sesses a single, enlarged HBS-1, similar to FGF9 [31], but
unlike FGF9 it may also possess an HBS3. The equivalent resi-
due in FGF9, Lys-202, was not found to be labelled in previous
work [31], which may be due either to only one protease being
used in this work or to the existence of a very well defined
Table 4. Summary of peptides of FGF17 identiﬁed by lysine-targeted protect and label. Labelled peptides were identiﬁed by MALDI-Q-TOF and analysed by
MS-digest from the package PROTEINPROSPECTOR v. 5.12.3. A full list of identiﬁed peptides is provided in the electronic supplementary material, table S1. The three
proteases used for protein digestion were thermolysin (THE), chymotrypsin (CHY) and Glu-C (GLU). The spectrums were shown in the electronic supplementary
material, ﬁgure S17–S21.
peptide sequence protease residue HBS spectrum
FGF17 1 GNK(biotin)FAK(biotin)LIVETD (GLU) 80–91 1 S17
2 GSRVRIK(biotin)GAESEK(biotin)Y (CHY) 94–107 1 S18
3 LIGK(biotin)PSGK(biotin)SK(biotin)DCVFTE (THE) 116–131 1 S19
4 IK(biotin)RLY (CHY) 175–179 2 S18
5 QGQLPFPNHAEK(biotin)QK(biotin)QF (CHY) 180–195 2 S18
Table 5. Summary of peptides of FGF20 identiﬁed by lysine-targeted protect and label. Labelled peptides were identiﬁed by MALDI-Q-TOF and analysed by MS-digest
from the package PROTEINPROSPECTOR v. 5.12.3. A full list of identiﬁed peptides is provided in the electronic supplementary material, table S1. The two proteases used for
protein digestion were thermolysin (THE) and chymotrypsin (CHY). The spectrums were shown in the electronic supplementary material, ﬁgure S22–S23.
peptide sequence protease residue HBS spectrum
FGF20 1 YLGMNDK(biotin)GEL (CHY) 118–127 1 S22
2 YGSEK(biotin)LTSECIF (CHY) 128–139 1 S22
3 K(biotin)HGDTGRRYF (CHY) 157–166 1 S22
4 LNK(biotin)DGTPRDGARSK(biotin)RHQK(biotin)FTH (THE) 169–189 1 S23
5 K(biotin)DLLMYT (CHY) 205–211 3 S22
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physically adjacent arginine residues in FGF20. FGF20 has
been found to exist as a non-covalent dimer in solution
[39,47], which is also true for the protein we have produced
(electronic supplementary material, figure S6). When the
enlarged HBS1 is mapped onto the dimer structure, the
HBS1 from both FGF20 monomers are joined to form a single
large heparin binding surface.4. Discussion
To resolve the extent to which molecular specificity under-
pins the interactions of proteins with HS, we have used the
phylogenetic relationship of the FGF family, established
from amino acid sequence, as a model system. The inter-
actions of FGFs and heparin/HS have been measured from
two perspectives: the structures in the polysaccharide
required for binding and the lysines in HBSs on the FGFs.
Taking the present results with previous ones [31,33,34]
provides the first comprehensive coverage of the structural
basis of the interactions of a protein family with sulfated poly-
saccharide structures. These data collectively encompass 11
paracrine FGFs, all of which bind HS, with at least two FGFs
from each of the subfamilies. The data follow a clear pattern,
which is not related to the overall charge density of the polysac-
charide (table 1 and Material and methods). FGF members
from the same subfamily have preference for binding polysac-
charide structureswith similar patterns of sulfation and length,
whereas FGFs from different subfamilies have muchmore pro-
nounced differences in these preferences (figure 13). Moreover,
FGFs from the same subfamily possess similar secondary
HS binding sites and their primary HBS1 have similararchitectures. Again, FGFs from different subfamilies have
different combinations of secondary HBS and their HBS1 dif-
fers, particularly with respect to the extent to which amino
acids that are distant in sequence, but physically close, contrib-
ute to the HBS1 (figure 13). Thus, in the FGF1 subfamily, both
FGF1 and FGF2 have similar preference for N-sulfate and 2-O-
sulfate, but FGF1 differs in that it also binds saccharide struc-
tures with 6-O-sulfated heparin [33]. This subfamily
possesses three HBSs, the primary HBS1 and the secondary
binding sites HBS2 and HBS3 [31,34,48]. In the FGF4 subfam-
ily, FGF4 prefers structures containing 2-O and N-sulfate,
whereas FGF6 binds strongly to structures with 2-O and
either 6-O- or NS. Compared with FGF4, FGF6 needs a slightly
larger structure for minimum binding (dp6). Both FGF4 and
FGF6 have a single secondary binding site, whichwould corre-
spond to HBS3 in the FGF1 subfamily. In the case of the FGF7
subfamily, FGF7 and FGF10 have preference for a similar pat-
tern of sulfation and oligosaccharide length. However, FGF3
barely binds to doubly desulfated heparin containing only
2-O-sulfate and it required large structures for full binding.
The putative HBS3 of FGF7 and HBS4 of FGF3, identified by
amino acid sequence alignment, contain arginine but not
lysine [31] (figure 8), so cannot be identified by our lysine-tar-
geted method. The protect and label data, when combined
with sequence alignment (figure 8), indicate that the FGF7
family possesses two secondary HBSs, HBS3 and HBS4, the
latter being physically orthogonal to the canonical HBS1.
FGF17 and FGF18, which are in the FGF8 subfamily, bind to
similar structures containing 6-O-sulfate and N-sulfate and
they contain a single secondary binding site, HBS2. In the
FGF9 subfamily, FGF9 and FGF20 show a similar preference
for 6-O-sulfated heparin. Whereas FGF9 prefers to bind to
structures containing N-sulfate rather than 2-O-sulfate, FGF20
K123
K176
K115
K119
K106
K82
K100
K82
FGF17
labelled lysines
predicted lysines
overlap
other residues
180°
(a) (b)
(c) (d)
K123
Figure 11. Position of biotinylated peptides in FGF17 (residues 33–178)
identified by structural proteomics mapped onto their predicted three-
dimensional structure. The published structure of FGF8 (PDB 2FDB) [46] was
used to generate a structure of FGF17. Labelled lysines are coloured in blue
and literature annotated and/or predicted lysines in HBS1 are coloured in
yellow. The lysines overlapping with the literature annotated and predicted
aligned canonical HBS1 lysines are coloured in green. (a,b) Ribbon diagram;
(c,d) corresponding molecular surface. (b,d) 1808 back view of (a,c).
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required larger structures for binding than FGF9, this could
be caused by its dimeric structure [39,47]. Both FGF9 and
FGF20 possess a single, enlarged HBS1. A secondary HBS3
was also been found in FGF20; whereas corresponding basic
residues are present in FGF9, in the latter, there is no negatively
charged border and so they are more likely to be part of an
extended HBS1. In contrast, in FGF20, these residues are sur-
rounded by a negative border, which would isolate them.
Consequently, FGF20 seems likely to have a distinct HBS3
and may, therefore, unlike FGF9, be able to cross-link HS
chains [49].
The expansion of the FGF family and its divergence into
subfamilies occurred through genome duplication events that
led to even more complex animal body plans and physiology
[19]. The present analysis indicates that the molecular speci-
ficity of the FGFs for particular structures in HS and the
pattern of secondary binding sites on the FGFs also underwent
a similar diversification. This implies that the molecular basis
of the interaction of FGFs with glycosaminoglycan has been
subjected to the same natural selection processes that gave
rise to an expanded FGF family, which is similar to what is
seen with respect to the specificity of FGFs for their receptor
tyrosine kinases (FGFR) [50,51] and borne out by an analysis
of the interactions of nine paracrine FGFs [32]. Therefore, thedifferences we observe in the structural basis of FGF–glycosa-
minoglycan interactions (figure 13) are likely to be linked to the
functional differences that exist between FGFs and between
their subfamilies. This has important ramifications in relation
to our understanding of protein–glycosaminoglycan inter-
actions. It is interesting to note that Caenorhabditis elegans and
Drosophila possess far fewer FGFs than mammals (two and
three, respectively) and synthesize simpler HS structures [52],
though whether there is a general link between the expansion
of HS binding proteins and more complex glycosaminoglycan
biosynthesis in evolution remains to be established.
The molecular specificity (figure 13) is far from absolute.
For example, there is a consensus ranking of sulfations, oligo-
saccharide length and glycosaminoglycan preference for
FGFs in the same subfamily, but this is not a simple one-to-
one code (figure 13). This raises the question of how specific
and selective protein–glycosaminoglycan interactions are, to
which there have been varied answers [30,53]. In this respect,
excellent binding structures in sulfated polysaccharides that
are unrelated to glycosaminoglycan have been identified for
some FGFs [54]. This supports the contention that it is the
spatial disposition of sulfate, carboxyl and hydroxyl groups
on the polysaccharide that are important for binding. The
sugar chain will adopt a variety of conformations in solution
and pendant sulfate groups will modify the conformational
space that the chain can occupy, which has been demon-
strated by NMR and CD studies [55]. In addition, the
coordination of cations modifies the conformation of the
polysaccharide chain [36]. Finally, while the binding to poly-
saccharide clearly changes the conformation of the protein, e.g.
thermal stabilization observed by DSF, the reverse is also true:
binding to protein alters the conformation of the polysacchar-
ide. The latter point is elegantly made by the co-crystal
structure of FGF2 and a heparin dp6, in which the latter has
iduronate residues in both the 1C4 and the
2S0 configurations
[56]. Thus, the selectivity and specificity identified here is
somewhat artificial, because the conformation of HS in vivo
in extracellular and pericellular matrix will depend on the
sequence of saccharides, the coordinated cations and the pre-
existing interactions of theHS chainwith endogenous proteins.
It is intriguing that at some level cells can sense what func-
tional structures they produce andmodify these. This is shown
by the HS 2-O sulfotransferase knockout mouse, which dies at
birth owing to kidney agenesis [57]. HS or heparin lacking
2-O-sulfate cannot bind FGF2 or form a productive ternary
complex with the FGFR [58]. Yet, the knockout mice have no
FGF2 phenotype [57]. Moreover, when embryonic fibroblasts
were derived from these mice, their HS did not possess any
2-O-sulfated HS, but the HS was capable of interacting with
FGF2 and enabling it to bind and activate FGFR on cells [59].
Thus, there would appear to be homeostatic mechanisms
whereby cells canmodify the chains they produce and perhaps
cations coordinated to HS and/or the endogenous proteins
bound to this HS, to ensure that as many as possible of the
appropriate functions are maintained after perturbation. Such
homeostatic plasticity can be considered to be advantageous,
because it provides for a robust rather than a brittle regula-
tion of cell communication. However, this clearly limits the
degree to which one can apply simple interpretations to
the molecular basis of specificity of FGF–glycosaminoglycan
interactions. This is likely to be true of protein–glycosamino-
glycan interactions in general. For example, in addition to its
classic pentasaccharide binding sequence [5], which has been
180°
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Figure 12. Position of biotinylated peptides in FGF20 (residues 33–178) identified by structural proteomics mapped onto three-dimensional structure. The pub-
lished structure of FGF20 (residues 33–178; PDB 3F1R) was used [47]. Labelled lysines are coloured in blue and literature annotated and/or predicted lysines in
HBS1 are coloured in yellow. The lysines overlapping with the literature annotated and predicted aligned canonical HBS1 lysines are coloured in green. (a,b) Ribbon
diagram; (c,d) corresponding molecular surface. (b,d) 1808 back view of (a,c). Labelled lysines and those overlapped with aligned HBS lysines are coloured in blue,
predicted lysines and arginines are coloured in red. Lysines that were both acetylated and biotinylated are coloured in green. b-strands are according to one
structure in each subfamily (FGF10, PDB 1NUN; FGF20, PDB 3F1R; FGF8, 2FDB; FGF4, PDB 1IJT).
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NS ª 2S ª 6S; dp4-dp10;       HS > DS;                  HBS1,2,3
NS ª 2S > 6S; dp6-dp10;          HS > DS;                  HBS1,3
6S ª NS > 2S; dp4-dp10;          HS ª DS > CS;          HBS1
6S ª NS > 2S; dp4-dp10;          HS > DS;                  HBS1,3
6S ª NS ª 2S; dp4-dp8;             HS > DS > CS;          HBS1,4
6S ª NS ª 2S; dp4-dp8;            HS > DS > CS;          HBS1,3,4
6S ª NS ª 2S; dp4-dp10;          HS > DS > CS;          HBS1,2
6S ª NS > 2S; dp6-dp10;          HS > DS;                  HBS1,2
2S > 6S, NS; dp6-dp10;            HS;                           HBS1,3
6S ª 2S > NS; dp10->dp12;      HS > CS ª DS;          HBS1,3
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Figure 13. The heparin structural preference of FGFs and their heparin binding sites. Asterisk denotes data from [31,33,34]. The preference of FGF members from
different subfamilies for the sulfation pattern, oligosaccharide length, glycosaminoglycan and binding sites of heparin structure.
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protein–HS interactions, there are good antithrombin III bind-
ing structures with anticoagulant activity that are substantially
different [27,28].The evolutionary divergence and, within FGF subfamilies,
conservation of HS binding properties, indicates that these
have functional importance. This is demonstrated by the
requirement for HS as a co-receptor for the formation of the
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[6,7]. However, HS binding has a range of other functions,
one of which is the regulation of the diffusion of FGFs in the
extracellular matrix. Thus, the measurement of the diffusion
of FGFs in the pericellular matrix of fibroblasts [8,60] shows
that the diffusion properties of FGFs are determined at least
in part by their binding specificities for glycosaminoglycans.
It is established that HS controls the transport and diffusion
of other HS-binding effectors, for example, in development
where HS binding influences morphogen gradients [13,61,62]
and in guiding immune cells [63]. The selectivity of HS
for different proteins, demonstrated here across the FGF
family, may enable differential yet simultaneous control of
the bioavailability and of gradients of numerous HS-binding
effectors. In terms of signalling, the FGFRs also bind to HS
and the ternary signalling ligand-receptor complex involves
the FGF ligand, HS co-receptor and FGFR. Work in cultured
cells indicates that in at least some instances the structure of
the polysaccharide can control the formation of signalling com-
plexes independently of ligand binding [54,64] and so the
selectivity of an FGF ligand–FGFR pair may differ from that
of the individual proteins [65]. Ternary signalling complexes
have been found in other families of HS-binding effectors, so
this mode of regulation may be more widespread. The diver-
gence of the HS binding properties of FGFs may have been
constrained by these impacting on different facets of FGFfunction and by the specificity code being three-dimensional,
rather than linear. The interaction of FGFR with HS and the
functional requirements of other families of HS-binding effec-
tors would then provide additional constraints on the
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